Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Caelyx and Cyclophosphamide followed by Docetaxel in LABC
NCT01206881Phase 2Completed
- Sponsor
- Herlev Hospital
- Start
- Mar 2009
- Primary completion
- May 2011
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in breast cancer, sponsored by Herlev Hospital. Primary endpoint: Clinical Response Rate at 24 weeks. Started Mar 2009; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01206881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01206881.